Navigation Links
MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years
Date:7/23/2009

DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.PK) (http://www.mitcanada.ca http://www.mitinvest.ca), "MIT" is pleased to announce that it has been granted a completely new, 8,000 square foot operation facility, as per "MIT China" requirements, from the "China Medical City" in Taizhou city for a period of 2 and half years.

The operation facility will harbor all the sub-assembly, final assembly and quality control of Agro-Jet and Med-Jet products to be sold to the Chinese market.

MIT China assembly operation is planned to start in September 2009.

Japanese patent

MIT is pleased to announce that it has obtained its first Japanese Patent from the Japanese Patent and Trademark Office for its Needle-Free Jet-Injector. Other similar international patents are pending. This first Japanese patent is another important achievement and recognition from a leading technological country like Japan. MIT will now expand even more into the world market. This technology offers a front-line means of prevention against pandemics, contributes to eliminate the possibility of both pre-injection contamination and post-injection cross-infection from needles/syringes, increases institutional sanitation, and protects human health.

Marketing and sales

MIT is actively promoting its MED-JET for human use for mass-inoculation. With the continuing outbreak of the "swine-flu" H1-N1 and the increased fear and awareness of the pandemic that could affect millions of people, we believe that Canada and the world market must use MIT's unique needle-free technology to deliver safely and effectively the vaccine to the world population.

Medical International Technology Inc. is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.

    Karim Menassa, President
    On Behalf of the Board of Directors        Tel: 514-339-9355

About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.


'/>"/>
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
7. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
10. Phylonix granted broad European patent for transplanting human cells into zebrafish
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: